ERBB2 and breast cancer: Metastatic disease: likelihood (OR with 95% CI and P values from logistic regression) of receiving trastuzumab by deprivation and adjusted for age, ethnicity, rural/urban residence, government region, grade, whether received surgery, ER status, comorbidities, whether discussed at MDT meeting, and diagnosis year for women with stage IV HER2+ breast cancer diagnosed between January 01, 2012 and December 31, 2017 (n = 2,369).